Skip to main content
| News

Basel researchers developing universal cancer therapy

26.01.2021

Researchers from Basel are working on the development of a therapy in which pre-prepared immune cells can be used to treat any form of cancer immediately after diagnosis. A startup now intends to use 30 million US dollars in seed funding to finance the transition towards clinical development.

Researcher and entrepreneur Lucia Mori (img: University of Basel, Oliver Hochstrasser)

Dr. Lucia Mori from the Department of Biomedicine at the University of Basel is working on the development of a revolutionary cancer therapy. According to a press release issued by the university, this would represent substantial progress even in comparison with personalized immune therapies. While these facilitate high-precision treatment, they also take time. “Wouldn’t it be great if we could just reach into the freezer following a cancer diagnosis, and have a ready-made pack of immune cells ready to go? Regardless of the type of cancer?”, Mori states, highlighting the key advantage of her solution.

Together with her colleagues, Mori, who was born in Italy, identified cells in the human immune system that would be able to attack various types of cancer cells as part of her research in Basel – “the best place in the world for immunological research”, she claims. These MR1T cells are able to detect tumors and attack MR1, which is a protein carried by nearly all cancer cells. In the lab, MR1T cells can be customized so that that they can be used to combat a whole host of cancer indications.

“Our aim is to manipulate T cells from healthy donors in such a way that they can target the combinations of MR1 and other characteristic molecules on the surface of cancer cells”, Mori explains in the press release. As these characteristics are often shared by the same cancer types, the relevant therapies could be prepared in advance. For example, this kind of treatment could be used to fight breast, bowel and lung cancers.

The focus is now on transitioning to clinical development. For this, Mori co-founded the startup Matterhorn Biosciences, which has already raised 30 million US Dollars in seed financing from Versant Ventures.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

BeiGene opens European headquarters in Basel
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

BeiGene opens European headquarters in Basel

BeiGene has opened its new European headquarters in Basel. The global biotech specializing in innovative cancer treatments intends to build...

Read More
The 25 Best AI Courses in the Basel Area, Germany and France
Advanced Manufacturing/AI, Basel Area Business & Innovation, Innovation

The 25 Best AI Courses in the Basel Area, Germany and France

Artificial Intelligence (AI) offers numerous possible applications. But how, where and regarding which focal points can you get further training...

Read More
Engimmune Therapeutics banks 15.5 million Swiss francs
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Engimmune Therapeutics banks 15.5 million Swiss francs

Engimmune Therapeutics will now be in a position to drive forward its innovative platforms for the development of T-cell therapies...

Read More
Bionter receives 3 million US dollars in investments
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Bionter receives 3 million US dollars in investments

Bionter AG has received 3 million US dollars in a seed funding round. These funds will enable Bionter to bring...

Read More
Resistell seeking to further develop test to combat antibiotic resistance
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Resistell seeking to further develop test to combat antibiotic resistance

The startup Resistell has launched a study looking into the applicability of a test against antibiotic resistances that is being...

Read More
Biotech startup Cimeio receives 46 million Swiss francs for cell therapy
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Biotech startup Cimeio receives 46 million Swiss francs for cell therapy

Cimeio Therapeutics from Basel has received initial financing amounting to 46 million Swiss francs from Versant Ventures. The startup is...

Read More
1 2 3 55

Do you have a question? We'd like to hear from you.